Teva Pharmaceutical Industries (NYSE:TEVA) Issues Quarterly Earnings Results

Posted by Geri Gentry on Nov 3rd, 2026

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) released its earnings results on Tuesday. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.14, FiscalAI reports. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The company had revenue of $4.39 billion for the quarter, compared to the consensus estimate of $4.23 billion. During the same period in the prior year, the company posted $0.78 EPS. The company’s revenue was down 1.9% compared to the same quarter last year.

Here are the key takeaways from Teva Pharmaceutical Industries’ conference call:

Teva raised its 2026 guidance, including revenue to $16.7–$17.0 billion and free cash flow to $2.1–$2.4 billion, supported by strong growth in AUSTEDO, AJOVY, and UZEDY. Non-GAAP EPS rose 10% year over year to $0.86, while gross margin expanded to 58.7%.
The innovative portfolio continued to accelerate: AUSTEDO reached its $2.5 billion sales target a year early, UZEDY revenue increased 96% to $85 million, and AJOVY revenue rose 61% to $269 million. Teva raised full-year product outlooks for all three brands and expects continued long-term growth.
FDA approval of WELTRUZA, a once-monthly long-acting olanzapine injection, expands Teva’s neuroscience franchise; management expects limited revenue in the first half of 2027 while payer coverage is established, with more meaningful contribution in the second half. Teva estimates the combined UZEDY/WELTRUZA franchise can reach $1.5–$2.0 billion in peak sales.
Biosimilars are becoming a major growth engine, with Teva achieving its $800 million 2027 sales target a year early and expanding to 15 marketed products plus a broader pipeline. The company also reached investment-grade ratings from all three major agencies and remains on track for net debt leverage of approximately 2x EBITDA by the end of 2027.
Generic revenue declined 16%, primarily because of lower generic REVLIMID contribution, and AUSTEDO is expected to decline year over year in Q4 due to purchasing patterns and pricing pressure ahead of IRA implementation. Separately, Teva discontinued the emrusolmin Phase II study after a futility analysis, although management reported no safety concerns.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $42.43 on Tuesday. Teva Pharmaceutical Industries has a 12 month low of $20.11 and a 12 month high of $42.75. The firm has a fifty day simple moving average of $39.14 and a 200 day simple moving average of $34.59. The stock has a market capitalization of $49.45 billion, a price-to-earnings ratio of 70.82, a PEG ratio of 3.71 and a beta of 0.89. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56.

Wall Street Analysts Forecast Growth

Several brokerages have commented on TEVA. Oppenheimer upped their target price on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, October 9th. HC Wainwright assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Monday. They set a “buy” rating and a $52.00 price target on the stock. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a report on Friday, September 4th. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus price target of $46.54.

Read Our Latest Stock Report on TEVA

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 367,600 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Brian Savage sold 7,342 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, September 18th. The shares were sold at an average price of $38.85, for a total transaction of $285,236.70. Following the completion of the sale, the insider owned 8,500 shares in the company, valued at $330,225. The trade was a 46.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 374,959 shares of company stock valued at $14,644,285. 0.54% of the stock is owned by insiders.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

Positive Sentiment: Q3 earnings beat expectations: Teva reported adjusted earnings of $0.86 per share, versus the $0.72 analyst consensus, while revenue of approximately $4.39 billion exceeded expectations of $4.23 billion. Revenue declined 1.9% year over year, but the earnings and sales beats provide support for the stock. Teva Pharmaceutical Q3 profit gain beats estimates
Positive Sentiment: UZEDY momentum strengthened: U.S. net sales of the schizophrenia treatment reached $85 million in the third quarter, up 96% year over year. Teva raised its 2026 UZEDY revenue outlook to $290–$310 million from $270–$290 million, signaling stronger growth for a key branded product. Medincell UZEDY third-quarter sales and outlook
Positive Sentiment: Biosimilar portfolio expanded: Teva signed an agreement with Samsung Bioepis to commercialize two FDA-approved U.S. immunology biosimilars. ETICOVO rights transfer upon closing, while infliximab-abda is expected to become available in the third quarter of 2027, supporting Teva’s generics and biosimilars strategy. Teva and Samsung Bioepis biosimilar agreement
Positive Sentiment: Analyst endorsement: HC Wainwright initiated coverage with a “buy” rating and a $52 price target, implying meaningful potential upside from the referenced share price.
Negative Sentiment: Neuroscience setback: Teva will discontinue the Phase 2 TOPAS-MSA study of emrusolmin for multiple system atrophy after an interim futility analysis indicated a low probability of meeting the primary efficacy endpoint. Although no safety concerns were identified, the decision removes a potential pipeline catalyst and was the primary source of selling pressure. Teva discontinues emrusolmin Phase 2 study

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.